Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Nondisplaceable Binding Is a Potential Confounding Factor in C-11-PBR28 Translocator Protein PET Studies

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: a NeuroPharm study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Structural brain abnormalities associated with cognitive impairments in bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Karolinska Schizophrenia Project Consortium
View graph of relations

The PET ligand 11C-PBR28 (N-((2-(methoxy-11C)-phenyl)methyl)-N-(6-phenoxy-3-pyridinyl)acetamide) binds to the 18-kDa translocator protein (TSPO), a biomarker of glia. In clinical studies of TSPO, the ligand total distribution volume, VT, is frequently the reported outcome measure. Since VT is the sum of the ligand-specific distribution volume (VS) and the nondisplaceable-binding distribution volume (VND), differences in VND across subjects and groups will have an impact on VTMethods: Here, we used a recently developed method for simultaneous estimation of VND (SIME) to disentangle contributions from VND and VS Data from 4 previously published 11C-PBR28 PET studies were included: before and after a lipopolysaccharide challenge (8 subjects), in alcohol use disorder (14 patients, 15 controls), in first-episode psychosis (16 patients, 16 controls), and in Parkinson disease (16 patients, 16 controls). In each dataset, regional VT estimates were obtained with a standard 2-tissue-compartment model, and brain-wide VND was estimated with SIME. VS was then calculated as VT - VND VND and VS were then compared across groups, within each dataset. Results: A lower VND was found for individuals with alcohol-use disorder (34%, P = 0.00084) and Parkinson disease (34%, P = 0.0032) than in their corresponding controls. We found no difference in VND between first-episode psychosis patients and their controls, and the administration of lipopolysaccharide did not change VNDConclusion: Our findings suggest that in TSPO PET studies, nondisplaceable binding can differ between patient groups and conditions and should therefore be considered.

Original languageEnglish
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume62
Issue number3
Pages (from-to)412-417
Number of pages6
ISSN0161-5505
DOIs
Publication statusPublished - Mar 2021

    Research areas

  • Artifacts, Brain/diagnostic imaging, Humans, Positron-Emission Tomography, Protein Binding, Pyrimidines/metabolism, Receptors, GABA/metabolism, translocator protein, 11C-PBR28, simultaneous estimation, PET, kinetic modeling

ID: 65897030